Sg3 Management, LLC Akero Therapeutics, Inc. Call Options Transaction History

Sg3 Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $286,979 - $386,848	-7,700 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $745,712 - $1.22 Million	22,300 Added 289.61%	30,000 $1.64 Million
Q3 2022 May 15, 2023	SELL	$10.15 - $34.05 $226,345 - $759,314	-22,300 Reduced 74.33%	7,700 $262,000
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $78,155 - $262,185	7,700 New	7,700 $262,000
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $496,200 - $647,000	-20,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $480,800 - $683,800	20,000 New	20,000 $580,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.49B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.